$0.310
-0.114 (-36.67%)At close
- High
- 0.361
- Open
- 0.346
- VWAP
- 0.32
- Volume
- 40.07M
- Mkt Cap
- —
- Low
- 0.283
- Amount
- 12.74M
- EV/EBITDA, TTM
- 0.00
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections.
AI analysis of Lakewood-Amedex Biotherapeutics Inc (LABT)
SellLakewood-Amedex Biotherapeutics Inc. (LABT) is not a good buy right now due to its extremely low current price of $0.31, a staggering year-to-date change of -99.70%, and a very low RSI of 7.114 indicating oversold conditions. The company has reported consistent losses, with a net income of -3772008.00 USD in Q2 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the stock has seen a 5-day change of -46.55%, reflecting significant downward momentum. The main risk is the company's ongoing financial struggles, as evidenced by its negative EPS of -4.42 and a current ratio of only 0.02, indicating potential liquidity issues.
Valuation Metrics
Events Timeline
News
9.010-21PRnewswireNu-3 Antimicrobial Shows Promise for Diabetic Foot Ulcers
9.010-07NewsfilterBisphosphocin® Class Antimicrobials Show Significant Efficacy in Animal Models
9.009-28PRnewswireLakewood-Amedex's Nu-3 Shows Promising Clinical Data in Antimicrobial Resistance Fight
- 9.009-28Newsfilter
Lakewood-Amedex's Nu-3 Shows Promising Clinical Data for Antimicrobial Resistance
9.009-24PRnewswireLakewood-Amedex Initiates Patient Dosing for Nu-3 Clinical Trial
LABT FAQ — answered by Alphio AI
Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections. It operates in the Healthcare sector.
Lakewood-Amedex Biotherapeutics Inc. (LABT) is not a good buy right now due to its extremely low current price of $0.31, a staggering year-to-date change of -99.70%, and a very low RSI of 7.114 indicating oversold conditions. The company has reported consistent losses, with a net income of -3772008.00 USD in Q2 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected. Additionally, the stock has seen a 5-day change of -46.55%, reflecting significant downward momentum. The main risk is the company's ongoing financial struggles, as evidenced by its negative EPS of -4.42 and a current ratio of only 0.02, indicating potential liquidity issues.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.